Fulcrum Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Fulcrum TherapeuticsDer Umsatz und der Gewinn des Unternehmens werden voraussichtlich um 5.4% bzw. 11.7% pro Jahr zurückgehen, während der Gewinn pro Aktie voraussichtlich zurückgehen wird.

Wichtige Informationen

-11.7%

Wachstumsrate der Gewinne

-8.4%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.6%
Wachstumsrate der Einnahmen	-5.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%

Sep 13

Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly

Sep 12

Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Jul 12

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Feb 11

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Oct 28

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Jul 11

What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Nov 17

We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Oct 18

Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13

Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M

Aug 11

Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave

Jul 11

Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder

Jul 05

Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling

Jun 27

These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

May 10

Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Apr 09

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Dec 09

Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point

Sep 03

Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

Aug 12

News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

Aug 11

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:FULC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	34	-58	-58	-57	5
12/31/2025	4	-93	-74	-50	8
12/31/2024	87	-19	-18	-5	9
6/30/2024	82	-20	-13	-12	N/A
3/31/2024	3	-99	-92	-92	N/A
12/31/2023	3	-97	-91	-91	N/A
9/30/2023	3	-99	-88	-88	N/A
6/30/2023	3	-98	-93	-92	N/A
3/31/2023	4	-109	-101	-99	N/A
12/31/2022	6	-110	-99	-97	N/A
9/30/2022	11	-107	-102	-99	N/A
6/30/2022	14	-104	-96	-94	N/A
3/31/2022	17	-90	-86	-84	N/A
12/31/2021	19	-81	-80	-78	N/A
9/30/2021	18	-75	-78	-76	N/A
6/30/2021	15	-73	-60	-58	N/A
3/31/2021	13	-69	-56	-55	N/A
12/31/2020	9	-71	-55	-54	N/A
9/30/2020	5	-69	-39	-38	N/A
6/30/2020	3	-68	-48	-47	N/A
3/31/2020	1	-68	-46	-45	N/A
12/31/2019	N/A	-90	-40	-39	N/A
9/30/2019	N/A	-85	-46	-41	N/A
6/30/2019	N/A	-79	-38	-32	N/A
3/31/2019	N/A	-71	-34	-26	N/A
12/31/2018	N/A	-39	-32	-23	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: FULC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: FULC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: FULC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: FULCDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-5.4% pro Jahr).

Hohe Wachstumseinnahmen: FULCDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-5.4% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von FULC in 3 Jahren voraussichtlich hoch sein wird

Fulcrum Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 1,613%

Price target increased by 7.5% to US$14.25

Consensus revenue estimates increase by 24%

Consensus revenue estimates fall by 15%

Price target increased by 9.8% to US$11.21

Price target increased by 31% to US$10.57

Recent updates

Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%

Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly

Fulcrum Therapeutics, Inc. Announces Executive Appointments

Fulcrum Therapeutics, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Consensus revenue estimates increase by 1,613%

Price target increased by 7.5% to US$14.25

First quarter 2024 earnings released: US$0.43 loss per share (vs US$0.41 loss in 1Q 2023)

Fulcrum Therapeutics, Inc. Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (ReDUX4) in The Lancet Neurology

Fulcrum Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Fulcrum Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Fulcrum Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 24%

CEO, President & Director recently bought US$492k worth of stock

Consensus revenue estimates fall by 15%

Fulcrum Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Fulcrum Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.8% to US$11.21

Fulcrum Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulcrum Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

New major risk - Share price stability

Price target increased by 31% to US$10.57

Fda Lifts Clinical Hold on Fulcrum Therapeutics' Ftx-6058 for Sickle Cell Disease

Consensus revenue estimates increase by 11%

Fulcrum Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer, Effective August 7, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulcrum Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Small Cap Comp Value Index

Levi & Korsinsky, LLP Notifies Fulcrum Therapeutics, Inc. Investors of Class Action Lawsuit and Upcoming Deadline

Consensus revenue estimates decrease by 31%, EPS upgraded

Fulcrum Therapeutics, Inc. Chief Executive Officer Changes

Price target decreased by 22% to US$7.56

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulcrum Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 17% to US$18.75

Price target increased by 11% to US$24.38

Insufficient new directors

President notifies of intention to sell stock

Fulcrum Therapeutics, Inc. Announces Resignation of Bryan Stuart from the Board of Directors

What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Consensus forecasts updated

Price target decreased to US$25.29

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulcrum Therapeutics, Inc. Announces Management Changes

Fulcrum Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Fulcrum Therapeutics, Inc. Announces Resignation of Judith A. Dunn as President, Research and Development

We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 Redux4 Study

Price target increased to US$30.71

Consensus revenue estimates fall by 17%

Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Fulcrum Therapeutics, Inc. Promotes Mel Hayes to the Chief Operating Officer

Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M

Fulcrum Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Fulcrum Therapeutics Announces Executive Changes

Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave

Fulcrum Therapeutics, Inc. Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy

Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder

Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling

Fulcrum Therapeutics Announces Proof-Of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1B Trial

Price target decreased to US$30.25

Consensus revenue estimates fall by 19%